Submitted by dcc on Thu, 2017-02-16 13:44 Study Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma<br>CIRB: Adult CIRB - Late Phase EmphasisLead Group: ECOGStatus: Closed to Accrual. Pts Still Rcving InterventionReview Status: Available to Open
